Repertoire Immune Medicines partners with Eli Lilly to develop tolerizing therapies for autoimmune diseases, receiving $85 ...

Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a strategic ...

Cambridge, Mass.— An exciting collaboration between the Ragon Institute and the Jameel Clinic at MIT has achieved a significant milestone in leveraging artificial intelligence (AI) to aid the ...

A vaccine developed against one strain of a virus is a remarkable achievement. But a “universal vaccine” that could protect from all forms of that pathogen is the holy grail. For decades, researchers ...

Writing in Scientific Reports, researchers from the Stiftung Tieraerztliche Hochschule Hannover and collaborators present the design and evaluation of an artificial poly-epitope sequence comprising 20 ...

Magnetic nanoparticles engineered T cells inside living mice and guided them into solid tumors, achieving over 90% tumor ...

LA JOLLA, CA—A new study, published recently in Nature Communications, offers the first-ever map of which parts of Chikungunya virus trigger the strongest response from the body's T cells. With this ...

A substantial proportion of patients with autoimmune diseases experienced a new side effect called local immune effector cell–associated toxicity syndromes (LICATS) after receiving chimeric antigen ...

The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...

Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing ...